Summary Immunohistological detection of P-glycoprotein (P-gp) with monoclonal antibody C219 was performed on serial sections of 37 neuroblastoma specimens representative of the different forms of the disease, from stage 1 ganglioneuroma to stage 4 neuroblastoma. Malignant cells, irrespective of their degree of maturation varying from neuroblasts to ganglion cells, were negative on all specimens. The expression of P-glycoprotein was detected in nine specimens, but it was restricted to normal cells within the tumour. In four specimens, C219 reacted with normal infiltrating cells in the stroma (i.e. monocytes, histiocytes or fibroblasts) representing 5 to 10% of the total population within the section; in three specimens, the residual adrenal gland was strongly positive, and in two ganglioneuromas, a weak reactivity of C219 was observed on a few satellite cells and schwann cells. Three of 15 biopsies obtained at diagnosis contained normal P-gp positive cells: two were classified as stage 1 ganglioneuromas; one was a typical stage 4 composite tumours with positive histiocytes and fibroblasts in the well-differentiated counterpart. Six of 22 biopsies obtained after patients had received our current protocol of chemotherapy contained normal P-gp positive cells: five were partially differentiated and necrotic under the effect of chemotherapy; only one positive specimen was classified as undifferentiated neuroblastoma. Among negative specimens from previously treated patients, one was obtained from a patient in relapse after high-dose chemotherapy and ABMT, two were obtained from patients who had not responded to induction therapy, and six from patients in partial remission after induction therapy. The clinical evolution was very similar in both groups of patients with P-gp negative or positive biopsies.
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These findings suggest that the quantitative assessment of MDR RNA by northern blotting on fresh homogenates is likely to overestimate its expression on neuroblastoma cells, and that the mechanism of chemoresistance in widespread neuroblastoma is less likely to be associated with P-gp expression.
The relationship between the overexpression of the 170 kD cell membrane glycoprotein (P-glycoprotein) and the phenomenon of multidrug resistance (MDR) has been clearly demonstrated in human tumour cell lines; P-glycoprotein (P-gp) functions as a drug-efflux pump which can be reversed in vitro by calcium channel blockers such as Verapamil (Gerlach et al., 1986; Rothenberg & Ling, 1989) . The overexpression of P-gp has been well documented in a number of tissues, including liver, colon, kidney and adrenal gland, in untreated human malignancies arising from these tissues, as well as in a variety of tumours after treatment (Bell et al., 1985; Gerlach et al., 1987; Ma et al., 1987; Epstein et al., 1989; Lai et al., 1989; Merkel et al., 1989; Thiebaut et al., 1989; CordonCardo et al., 1990; Weinstein et al., 1990; Miller et al., 1991) . However, a meaningful relationship between the overexpression of P-gp and the resistance of these tumours to chemotherapy in vivo is not yet clear. Controversial conclusions have been reported on the incidence of P-gp mRNA expression in neuroblastoma and its ability to predict the resistance of widespread disease to chemotherapy (Goldstein et al., 1990; Bourhis et al., 1989; Nakagawara et al., 1990) . Discrepancies may easily be accounted for by the use of molecular techniques on bulk tissue in which the tumour cell fraction is usually unknown; neuroblatoma specimens are highly heterogeneous and often contaminated with residual adrenal gland or kidney which express high levels of P-gp mRNA. Conversely, immunohistochemistry can provide a direct morphological confirmation of the presence of P-gp in individual cells within the tumour (Schlaifer et al., 1990 Cordon-Cardo et al., 1990; Schlaifer et al., 1990; Dalton et al., 1989; Sugawara et al., 1989; Broxterman et al., 1989) . C219 monoclonal antibody is directed to a well-conserved cytoplasmic domain of the P-gp and its staining intensity correlates directly to the degree of resistance to drug influx in the cells . This reserved for routine paraffin-embedded haematoxylin-eosin-stained histological analysis, one was kept for molecular analysis, and the third one was frozen in isopentane and used in this study for immunohistological analysis of P-gp expression. Tumours were histologically classified as typical neuroblastoma when they were fully undifferentiated with a poor stroma, as ganglioneuroblastoma when they were partially differentiated with a rich stroma, and as ganglioneuroma when they were well differentiated.
Alkaline phosphatase immunostaining P-gp was recognised by C219 mouse monoclonal antibody (Centocor-Europ). Results were confirmed in four selected specimens with MRK16 mouse monoclonal antibody (Hamada & Tsuruo, 1986) . Immunochemical staining was performed using an indirect three-step immunoenzymatic procedure with alkaline phosphatase (Dakopatts, Copenhagen, Denmark), as already described (Combaret et al., 1989a To allow a more precise morphologic identification of the neoplastic and non-neoplastic cell populations, four positive biopsies were processed according to the ModAMeX method recently described in detail by Delsol et al. (1989) DNA analysis N-myc amplification was quantified by southern-blot technique, as previously described (Combaret et al., 1989b) . After extraction, 10 ytg DNA from each sample were digested with restriction enzyme EcoRl and separated by agarose gel electrophoresis (1%). DNA fragments were denatured and transferred to a nylon membrane (Gene Screen plus, DuPont). Hybridisation was performed with the N-myc probe pNb-I (kindly provided by J. Minna, NCI), 32P-labelled by Amersham 'Multi Primer Labelling System' to a specific activity of about I0O c.p.m. ig-'. Restriction enzyme-digested tumour DNAs were compared with lymphocyte DNA in the same agarose gels and with the known N-myc amplified DNA of a neuroblastoma cell line (SKNBE). The number of amplified gene copies was measured by serial dilution of DNA to obtain a hybridisation signal of two copy intensity (e.g. a 100-fold amplification is indicated when a 1:100 dilution achieves two-copy intensity).
Results
Immunohistological detection of P-gp recognised by C219 was performed on 37 neuroblastoma specimens representative of the different forms of the disease, from localised ganglioneuroma to metastatic neuroblastoma. Malignant cells, irrespective of their degree of maturation, from neuroblasts to ganglion cells, were negative in the 37 specimens. A positive immunostaining was detected on nine specimens but P-gp expression was restricted to normal cells. Eight of these nine positive specimens were classified histologically as ganglionneuroblastomas or ganglioneuromas, whereas only one was classified as undifferentiated neuroblastoma.
The negativity of malignant cells and the positivity of normal cells were confirmed on four selected specimens (no 1, 15, 22 and 26) with monoclonal antibody MRK16. Fifteen biopsies from patients with stage 1 to 4 or 4S disease were obtained at diagnosis (Table I) : three contained normal P-gp positive cells. In two specimens classified as stage I ganglioneuromas (patients no 1 and 3; photographs I and J), 5% of schwann cells and satellite cells weakly reacted with C219. The third specimen was a typical composite stage 4 neuroblastoma: the immature counterpart of the tumour was negative but, in the well-differentiated counterpart, 5 to 10% monocytes, histiocytes and fibroblasts expressed P-gp (patient no 15; photographs C and D for C219 reactivity, and E for MRK16 activity).
Twenty-two biopsies were obtained from patients with stage 3, 4 or 4S disease after they had received our current protocol of chemotherapy (Table II) . In most samples, chemotherapy had induced a partial differentiation of the tumour and infiltration by monocytes and histiocytes in the necrotic area. Six specimens contained normal P-gp positive cells; in three of them (no 22, no 26 and no 32), 5 to 10% infiltrating monocytes, histiocytes, and fibroblasts expressed P-gp (photographs F, G and H); in the other three cases, a strong positivity was observed on residual adrenal gland (no 23, 24 and 35; photographs K, and L). Sixteen of this series of 22 specimens obtained from pre-treated patients were negative, including specimens obtained from two patients who had not responded to induction therapy, from six patients in partial remission after induction therapy, as well as biopsies obtained from one patient in relapse after megatherapy and ABMT (see column 'clinical status at time of biopsy' in Table II) .
The presence of normal P-gp positive cells within the samples did not predict either response to subsequent courses of chemotherapy or clinical evoluation. Two of the nine positive biopsies were obtained from patients (no 1 and no 3) with stage 1-2 disease, who are well and free of disease without any chemotherapy. The other seven were obtained from patients with stage 4 disease: two patients, who received no consolidation with megatherapy because they were under 1 year old (no 15 and no 35), are in complete remission after induction therapy (10 months, 11 months + ); one patient (no 24) is in complete remission (36 months +) after megatherapy; four patients (no 22, no 23, no 26 , no 32) relapsed after megatherapy. This pattern of evolution is usual in children suffering from neuroblatoma. Finally, southern-blot analysis of the N-myc oncogene was performed in 30 of the 37 specimens; N-myc amplification was present in six specimens, including two P-gp positive biopsies. N-myc amplification was restricted to stage 3 and 4 neuroblastoma samples and its presence in P-gp positive and negative specimens reflected the usual incidence of this molecular defect in neuroblastoma. Table II and subsequent clinical evolution in Table I and II were evaluable according to our published rules (Philip et al., 1987) . Figure 1 Immunoreactivity of normal cells with C219 on sections of neuroblastoma tumours. a, b, c, d and e: sections ( x 128) from typical stage 4 composite tumour analysed at diagnosis (ppt no 15): Analysis of the P-gp expression was performed in serial sections with two control slides: one of the staining of neuroblastoma with UJ13A a, the other one for the staining of lymphocytes, monocytes or histiocytes with CD45 b; these two immunostainings also permitted to control the quality of preservation and fixation. P-gp positive cells were stained with C219 (c and d) and MRK16 (e): in the mature counterparts, fibroblasts and clumps of histiocytes are positive; the immature counterpart is negative (the tumour has been processed with the ModAMeX method to allow a more precise identification of neoplastic and non-neoplastic cells (Weinstein et al., 1990) , its reactivity on adrenal gland and normal stromal cells within neuroblastoma specimens is thus very likely to be P-gp specific.
The negativity of malignant cells in all specimens, from neuroblastoma to ganglioneuroma, questions the role of P-gp in the resistance of widespread neuroblastoma to chemotherapy. In agreement with our results, Cordon-Cardo et al. (1990) found no reactivity of seven neuroblastoma specimens with C219, HYB-241 and HYB-612, whereas 53 of the other 175 tumours they analysed strongly reacted with those three antibodies. However, in three other studies, a significant expression of MDR1 mRNA was detected in neuroblastoma specimens, though data and conclusions drawn by the authors were controversial. Bourhis et al. (1989) detected MDR1 mRNA in 12 of the 41 analysed specimens, and Goldstein et al. (1990) in eight out of 49; both concluded to its potential role in the chemoresistance of advanced neuroblastoma, based on the fact that the number of positive specimens was higher in series analysed after the patient had received chemotherapy than in series analysed at diagnosis. Conversely, Nakagawara et al. (1990) detected MDR1 mRNA in well-differentiated low-stage disease rather than in advanced stage 4 disease with N-myc amplification; the analysis of tumours obtained from patients with progressive disease and/or in relapse were negative, and a sequential study of tumours at diagnosis and after failure of chemotherapy did not demonstrate any increase in the MDR1 mRNA level.
The expression of P-gp on normal cells in neuroblastoma specimens, as shown here, can help to explain these data. First, the contamination of neuroblastoma specimens by kidney or residual adrenal gland may well account for the detection of MDR1 mRNA in some samples; MDR1 mRNA measured in the adrenal gland is usually 10-fold higher than levels observed in neuroblastoma specimens (Fojo et al., 1987; Bourhis et al., 1989; Goldstein et al., 1990) . The presence of kidney or residual adrenal gland within surgical specimens of neuroblastoma is not unusual in the case of invasive tumours; in our series, residual adrenal gland was still detectable in three specimens, although cryostat examination had been performed on all samples in order to cryopreserve only the most representative counterpart of the tumour. -Second, normal infiltrating cells expressing P-gp were usually detected in the rich stroma of partially or well-differentiated neuroblastoma; hence, the detection of Pgp mRNA in well-differentiated specimens rather than in undifferentiated neuroblastoma with a poor stroma in the series of Nakagawara et al. (1990) is not surprising. Third, chemotherapy is known to induce a partial differentiation of stage 4 neuroblastoma, together with an histiocytic infiltration around the necrotic area; P-gp expression by normal stromal cells, as observed in our study, may thus partially account for a more frequent detection of MDR1 mRNA in stage 4 tumours of previously treated patients than in those of untreated patients (Goldstein et al., 1990; Bourhis et al., 1989) .
Other authors have made retrospective attempts to correlate P-gp expression with clinical drug-resistance in various tumours, but conclusions from the different studies are still very controversial and further investigation is needed to establish the clinical significance of this finding, its relation with other biological features of the tumours and, eventually, the potential use in clinics of the P-gp multidrug transfer activity inhibition (Chabner & Wilson, 1991) . The occurrence of P-gp expression was until recently described in cell cultures only; discrepancies between the results of multidrug resistance analyses in tumoral specimens and in cell lines derived from malignant tissues of similar histology have now been well-documented in breast, ovarian or lung cancers (Merkel et al., 1989; Ozols et al., 1987; Lai et al., 1989 ). An overexpression of MDR1 mRNA by differentiating agents had also been induced in vitro in a neuroblastoma cell line (Bates et al., 1989) , but our data understate the role of P-gp in neuroblastoma chemoresistance in vivo.
In conclusion, the limitations of some laboratory tests used to stratify patients into drug-sensitive and drug-resistant categories, such as the inability to discriminate between normal and malignant cells when bulk tissues are analysed, must be taken into consideration when correlating drug-resistance and P-gp expression. The demonstration that P-gp expression was restricted to normal cells within sections of neuroblastoma specimens requires reconsideration of its role in the chemoresistance of this disease. In particular, the preferential expression of MDR1 mRNA in tumours from previously treated patients cannot be interpreted as the acquisition of resistance to chemotherapy as long as direct morphologic examination does not confirm the presence of P-gp in the malignant cells. Although we cannot rule out that some neuroblastoma cells may weakly express MDR1, this probably concerns very few tumoural specimens. Any further attempt to evaluate the clinical relevance of P-gp expression in neuroblastoma will require the analysis of both MDR1 mRNA and MDR protein at cell level; the development of in situ hybridisation with nucleic adic probes on tissue sections will help in the arrival at definitive conclusions.
